In a major milestone for mental health care, Austin-based Choose Your Horizon Inc., also known as Choose Ketamine, has announced the completion of its seed financing round. Led by Manifestations Capital in collaboration with Notley Ventures and numerous industry veterans and thought leaders, this will enable the company to expand its ketamine therapy platform across the US. Choose Ketamine was founded in 2021 with the intention of providing affordable and accessible treatments to those suffering from depression, anxiety and PTSD
Read More
The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it has been granted a Pre-Investigational New Drug (Pre-IND) meeting by the U.S. Food and Drug Administration (FDA) for new chemical entity Triptax™. Biomind Labs is devoted to crafting innovative pharmaceuticals for patients with neurological and psychiatric disorders,
Read More
Popular
WHAT'S NEW AND HAPPENING IN PSYCHEDELICS
Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patents strengthening the company’s intellectual property portfolio.
Read More
Zylorion announced today the filing of the Company’s third provisional patent application with the United States Patent and Trademark Office (“USPTO”). The provisional patent
Read More
The nation’s largest ketamine therapy provider now offers complimentary patient resources supporting holistic mental health treatment. On Thursday, the largest ketamine therapy provider Ketamine
Read More
The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it has been granted a Pre-Investigational New Drug
Read More
At Psychedelic Chronicle our team not only delivers the latest news regarding the psychedelic industry ranging from medical research to industry analysis, but we also aim to provide comprehensive coverage of the
Keep ReadingLATEST PSYCHEDELIC NEWS
atai has administered the first dosage of their VLS-01 synthetic DMT drug in their Phase 1 single-ascending dose (SAD) trial, with topline results expected to come back sometime during the
Read More
Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patents strengthening the company’s intellectual property portfolio. The company which focuses on developing
Read More
Leading psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) has announced the completion of dose administration to 30 healthy subjects with Treatment-Resistant Depression in the Phase
Read More
